Ascorbate
Phase 3Small molecule
Ascorbate is one of 44 small molecule programs targeting Gemcitabine. It is currently in Phase 3.
2
Indications
11
Total Trials
3
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Ascorbate
FFudan University
Phase 3
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer4 trials
A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients
Withdrawn·—·Phase 2·NCT03541486
Gemcitabine3 trials
Gemcitabine Plus Ascorbate for Sarcoma in Adults
Terminated·—·Phase 2·NCT03468075·10 enrolled
Soft Tissue Sarcoma1 trial
Schizophrenia1 trial
Treatment of Acute Schizophrenia With Vitamin Therapy
Completed·—·Phase 4·NCT00140166·55 enrolled
Glioblastoma Multiforme1 trial
A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Completed·—·Phase 1·NCT01752491·13 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ascorbate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFudan University